Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Keros Therapeutics Inc shares valued at $9,464,512 were purchased by ADAR1 Capital Management, LLC on Apr 09 ’25. At $10.13 per share, ADAR1 Capital Management, LLC acquired 934,258 shares. The insider’s holdings grew to 4,392,737 shares worth approximately $66.37 million following the completion of this transaction.
Also, GORDON CARL L sold 250,000 shares, netting a total of over 11,002,500 in proceeds. Following the sale of shares at $44.01 each, the insider now holds 119,522 shares.
Before that, ORBIMED ADVISORS LLC had sold 250,000 shares from its account. In a trade valued at $11,002,500, the Director traded Keros Therapeutics Inc shares for $44.01 each. Upon closing the transaction, the insider’s holdings decreased to 250,000 shares, worth approximately $1.81 million.
As published in a research note from Cantor Fitzgerald on January 21, 2025, Keros Therapeutics Inc [KROS] has been rated down from an Overweight to a Neutral. Analysts at Wedbush downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in mid January. As of December 16, 2024, Oppenheimer has reiterated its “an Outperform” rating for KROS. Earlier on December 16, 2024, Guggenheim downgraded its rating. Their new recommendation was “a Neutral” for KROS stock which previously was a “a Buy”.
Analyzing KROS Stock Performance
During the last five days, there has been a surge of approximately 7.77%. Over the course of the year, Keros Therapeutics Inc shares have dropped approximately -4.55%. Shares of the company reached a 52-week high of $16.70 on 01/02/25 and a 52-week low of $9.12 on 04/09/25.
Support And Resistance Levels for Keros Therapeutics Inc (KROS)
According to the 24-hour chart, there is a support level at 14.76, which, if violated, would cause prices to drop to 14.40. In the upper region, resistance lies at 15.35. The next price resistance is at 15.58. RSI (Relative Strength Index) is 64.43 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Keros Therapeutics Inc (KROS)?
On December 13, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $47.
